LoValTech
Lovaltech is a French DeepTech startup founded in 2022, dedicated to developing a new generation of protein-based nasal vaccines. Their mission is to create vaccines that induce broad-spectrum immune responses and block transmission of infectious diseases, with a focus on COVID-19. They aim to revolutionize immunization by providing effective, easy-to-administer, and thermostable nasal vaccines that can prevent both disease and contagion, contributing to global health security.
Industries
Nr. of Employees
small (1-50)
LoValTech
49 Bd Preuilly, 37000 Tours
Products
Intranasal protein vaccine clinical candidate
A protein subunit intranasal vaccine candidate composed of a multivalent recombinant fusion antigen combined with a muco-adhesive excipient, developed to induce mucosal and systemic immunity and reduce viral transmission.
Intranasal protein vaccine clinical candidate
A protein subunit intranasal vaccine candidate composed of a multivalent recombinant fusion antigen combined with a muco-adhesive excipient, developed to induce mucosal and systemic immunity and reduce viral transmission.
Services
Design and management of non-clinical immunogenicity and toxicology studies to generate data required for regulatory submissions.
Coordination of GMP production, technology transfer and release activities with contract manufacturing organizations for protein vaccines and excipients.
Preparation of regulatory documentation (e.g., IMPD) and interaction with national regulators to obtain clinical trial approvals.
Definition of device requirements and collaboration with device manufacturers to develop spray systems compatible with vaccine formulations and scalable production.
Design and management of non-clinical immunogenicity and toxicology studies to generate data required for regulatory submissions.
Coordination of GMP production, technology transfer and release activities with contract manufacturing organizations for protein vaccines and excipients.
Preparation of regulatory documentation (e.g., IMPD) and interaction with national regulators to obtain clinical trial approvals.
Definition of device requirements and collaboration with device manufacturers to develop spray systems compatible with vaccine formulations and scalable production.
Expertise Areas
- Intranasal vaccine development
- Mucosal immunology
- Protein engineering and recombinant antigen design
- Preclinical efficacy and transmission modelling
Key Technologies
- Protein subunit vaccines
- Recombinant fusion protein antigens
- Muco-adhesive nanocarriers / muco-excipients
- Intranasal spray/aerosol delivery systems
News & Updates
Announcement of the regulatory approval for clinical trials of the MUCOBOOST nasal COVID-19 vaccine.
Recognition of Lovaltech's innovation and success in developing a nasal COVID-19 vaccine.
Scientific article discussing the design and efficacy of a nasal vaccine against COVID-19.
Lauréate du concours national i-Lab 2022
Lovaltech won the national i-Lab competition in 2022, supporting its innovative vaccine development.
Support from MESRI and ANRS-MIE for vaccine development
Initial funding and support for GMP production and clinical development of the vaccine.
Announcement of the regulatory approval for clinical trials of the MUCOBOOST nasal COVID-19 vaccine.
Recognition of Lovaltech's innovation and success in developing a nasal COVID-19 vaccine.
Scientific article discussing the design and efficacy of a nasal vaccine against COVID-19.
Lauréate du concours national i-Lab 2022
Lovaltech won the national i-Lab competition in 2022, supporting its innovative vaccine development.
Support from MESRI and ANRS-MIE for vaccine development
Initial funding and support for GMP production and clinical development of the vaccine.